Management of mother-to-child transmission of hepatitis B virus: Propositions and challenges

AbstractChronic hepatitis B virus (HBV) infection due to mother-to-child transmission (MTCT) during perinatal period remains an important global health problem. Despite standard passive–active immunoprophylaxis with hepatitis B immunoglobulin (HBIG) and hepatitis B vaccine in neonates, up to 9% of newborns still acquire HBV infection, especially these from hepatitis B e antigen (HBeAg) positive mothers. Management of HBV infection in pregnancy still need to draw careful attention because of some controversial aspects, including the failure of passive-active immunoprophylaxis in a fraction of newborns, the effect and necessity of periodical hepatitis B immunoglobulin (HBIG) injection to the mothers, the safety of antiviral prophylaxis with nucleoside/nucleotide analogs, the benefit of different delivery ways, and the safety of breastfeeding. In this review, we highlight these unsettled issues of preventive strategies in perinatal period, and we further aim to provide an optimal approach to the management of preventing MTCT of HBV infection

A comprehensive approach to developing a multi-epitope vaccine against Mycobacterium tuberculosis: from in silico design to in vitro immunization evaluation

IntroductionThe Bacillus Calmette-Guérin (BCG) vaccine, currently used against tuberculosis (TB), exhibits inconsistent efficacy, highlighting the need for more potent TB vaccines.Materials and methodsIn this study, we employed reverse vaccinology techniques to develop a promising multi-epitope vaccine (MEV) candidate, called PP13138R, for TB prevention. PP13138R comprises 34 epitopes, including B-cell, cytotoxic T lymphocyte, and helper T lymphocyte epitopes. Using bioinformatics and immunoinformatics tools, we assessed the physicochemical properties, structural features, and immunological characteristics of PP13138R.ResultsThe vaccine candidate demonstrated excellent antigenicity, immunogenicity, and solubility without any signs of toxicity or sensitization. In silico analyses revealed that PP13138R interacts strongly with Toll-like receptor 2 and 4, stimulating innate and adaptive immune cells to produce abundant antigen-specific antibodies and cytokines. In vitro experiments further supported the efficacy of PP13138R by significantly increasing the population of IFN-γ+ T lymphocytes and the production of IFN-γ, TNF-α, IL-6, and IL-10 cytokines in active tuberculosis patients, latent tuberculosis infection individuals, and healthy controls, revealing the immunological characteristics and compare the immune responses elicited by the PP13138R vaccine across different stages of Mycobacterium tuberculosis infection.ConclusionThese findings highlight the potential of PP13138R as a promising MEV candidate, characterized by favorable antigenicity, immunogenicity, and solubility, without any toxicity or sensitization

Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: A Systematic Review

Chronic viral hepatitis B remains a global public health concern. Currently, several drugs, such as tenofovir and adefovir, are recommended for treatment of patients with chronic hepatitis B. tenofovir is a nucleoside analog with selective activity against hepatitis b virus and has been shown to be more potent in vitro than adefovir. But the results of trials comparing tenofovir and adefovir in the treatment of chronic hepatitis B were inconsistent. However, there was no systematic review on the comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B. To evaluate the comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B we conducted a systematic review and meta-analysis of clinical trials. We searched PUBMED, Web of Science, EMBASE, CNKI, VIP database, WANFANG database, the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Review. Finally six studies were left for analysis which involved 910 patients in total, of whom 576 were included in tenofovir groups and 334 were included in adefovir groups. At the end of 48-week treatment, tenofovir was superior to adefovir at the HBV-DNA suppression in patients[RR = 2.59; 95%CI(1.01-6.67), P = 0.05]. While there was no significant difference in the ALT normalization[RR = 1.15; 95%CI(0.96-1.37), P = 0.14], HBeAg seroconversion[RR = 1.32; 95%CI(1.00-1.75), P = 0.05] and HBsAg loss rate[RR = 1.19; 95%CI(0.74-1.91), P = 0.48]. More high-quality, well-designed, randomized controlled, multi-center trails are clearly needed to guide evolving standards of care for chronic hepatitis B

Light-Driven Spiral Deformation of Supramolecular Helical Microfibers by Localized Photoisomerization

Stimuli-responsive mechanical deformations widely occur in biological systems but the design of biomimetic shape-changing materials, especially those based on noncovalent interactions, remains highly challenging. Here, hydrogen-bonded supramolecular microfibers are reported, which can perform light-driven spiral deformation by switching an intrinsic azobenzene unit without monomer dissociation. The key design feature rests on rationally spaced multiple hydrogen bonds, which inhibits the disassembly pathway upon irradiation, allowing partial photomechanical actuation of the azobenzene cores in the confined environment of the assemblies. The light-controlled deformation process of the supramolecular microfibers can be switched in a fully reversible manner. This combination of confinement-inhibited disassembly and photoswitching to induce assembly deformation and actuation along length scales supports a distinctive strategy to design supramolecular materials with photomechanical motion

Layer combination design and effect evaluation of phase change cooling asphalt pavement

Asphalt mixture is a temperature sensitive material. With the change of external environment temperature, asphalt pavement is prone to temperature-related diseases. Adding phase change material (PCM) to asphalt pavement to adjust pavement temperature is one of the effective methods at present. At present, there are many types of research on PCMs, but the research on PCMs added to the pavement structure is very scarce. In this paper, through the temperature test of rutting plate specimens with different layer combinations, the cooling effect of pavement structure combinations with PCMs added to different layers (upper layer, middle layer, and bottom layer) in pavement structure under different illumination times are discussed. Through the self-designed environmental simulation box, the real-time monitoring of the temperature of different layers in the pavement structure is realized. The cooling effect between different layers in different phase change pavement structure combinations is analyzed, and compared with each layer of ordinary pavement structure, and the best addition method is obtained for phase change materials, which provides a certain reference for the construction and specific application of PCM asphalt pavement, and made important contributions to the development of asphalt cooling pavement. The results show that the PCM can effectively reduce the temperature of each layer of the pavement structure. Under different illumination durations, the cooling effect of the samples with PCM in the upper layer was the worst. The samples with phase change material in the middle layer had the best cooling effect in the upper and middle layers of the pavement. The addition of phase change material to both the upper and middle layers had the most obvious cooling effect on the lower layer of the pavement. Therefore, combined with the comprehensive consideration of economy and cooling effect, the comprehensive cooling effect of adding PCMs to the middle surface layer is the best. It is recommended to add phase change materials to the middle surface layer during asphalt cooling pavement construction